Enter Note Done
Go to previous page in this tab
Session
  • Presentation | General Poster Session - Sunday General Poster Session
  • General Poster Session
  • Share Icon
    Map Icon
    Bookmark Icon
  • 837-P - Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (HRS-7535) in Type 2 Diabetes Mellitus Patients Inadequately Controlled by Metformin [Board No. 837]
    • Schedule
    Notes
  • Location IconPoster Hall (Hall F1)
    136
    Set Timezone

L.Guo: Research Support; ; Abbott, AstraZeneca, Bayer Pharmaceuticals, Inc, Eli Lilly and Company, Innovent Biologics, Merck & Co., Inc, MSD Life Science Foundation, Novo Nordisk A/S, Sanofi, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Tonghua Dongbao. Z.Sun: None. L.Zhang: None. G.Qin: None. Y.Li: None. Z.Ye: Employee; ; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Y.Xu: Employee; ; Jiangsu Hengrui Pharmaceuticals Co., Ltd. C.Shu: Employee; ; Jiangsu Hengrui Pharmaceuticals Co., Ltd.. P.Liu: Employee; ; Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Type
Main Session